A study from an international registry of over 1400 IBD patients suggested that combined therapy of a TNF antagonist and thiopurine was associated with an increased risk of severe SARS-CoV-2 outcomes, defined as a composite of mechanical ventilation, ICU admission, or death [7]. The gene discussed is TNF; the disease is inflammatory bowel disease.